Minneapolis
89°F
eEdition
News & Politics
Sports
Food & Culture
Business
Outdoors
Opinion
Things To Do
Obituaries
More of What Matters to Minnesota
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Minnesota State Top Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Corcept Therapeutics
(NQ:
CORT
)
34.79
+0.51 (+1.49%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
394,339
Open
34.51
Bid (Size)
32.20 (1)
Ask (Size)
35.79 (1)
Prev. Close
34.28
Today's Range
34.28 - 35.29
52wk Range
20.87 - 39.75
Shares Outstanding
115,926,629
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
NASDAQ:CORT: a strong growth stock preparing for the next leg up?.
August 16, 2024
CORCEPT THERAPEUTICS INC (NASDAQ:CORT)—Positioned as a High-Growth Stock, Ready for a Potential Breakout.
Via
Chartmill
NASDAQ:CORT is not too expensive for the growth it is showing.
August 05, 2024
Don't overlook NASDAQ:CORT—a stock with solid growth prospects and a reasonable valuation.
Via
Chartmill
Performance
YTD
+44.00%
+44.00%
1 Month
-0.23%
-0.23%
3 Month
+10.06%
+10.06%
6 Month
+50.41%
+50.41%
1 Year
+9.64%
+9.64%
More News
Read More
Unveiling 8 Analyst Insights On Corcept Therapeutics
July 30, 2024
Via
Benzinga
CORT Stock Earnings: Corcept Therapeutics Beats EPS, Beats Revenue for Q2 2024
July 29, 2024
Via
InvestorPlace
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
July 29, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
6 Analysts Have This To Say About Corcept Therapeutics
June 17, 2024
Via
Benzinga
NASDAQ:CORT is not too expensive for the growth it is showing.
May 31, 2024
Via
Chartmill
Corcept Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
May 29, 2024
Via
Benzinga
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
July 22, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Why NASDAQ:CORT Is a Promising High-Growth Stock in the Midst of Consolidation.
July 15, 2024
Via
Chartmill
Investors seeking growth at a reasonable cost should explore NASDAQ:CORT.
July 15, 2024
Via
Chartmill
7 Biotech Stocks to Boost Your Portfolio to Peak Health
June 26, 2024
Via
InvestorPlace
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for June 2024
June 26, 2024
Via
InvestorPlace
Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association’s Scientific Sessions
June 24, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
While growth is established for NASDAQ:CORT, the stock's valuation remains reasonable.
June 24, 2024
Via
Chartmill
Concerpt Therapeutics Shares Are Trading Lower: What You Need To Know
June 14, 2024
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session
June 14, 2024
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
June 03, 2024
Via
Benzinga
Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing’s Syndrome)
June 03, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
Nvidia, Insmed, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
May 28, 2024
Via
Benzinga
Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
May 28, 2024
Via
Benzinga
Why Mid-Cap Corcept Therapeutics Stock Trading Higher On Tuesday?
May 28, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
May 28, 2024
Via
Benzinga
Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing’s Syndrome)
May 28, 2024
From
Corcept Therapeutics Incorporated
Via
GlobeNewswire
While growth is established for NASDAQ:CORT, the stock's valuation remains reasonable.
May 10, 2024
Via
Chartmill
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.